| Company Name: |
ShangHai Caerulum Pharma Discovery Co., Ltd.
|
| Tel: |
18149758185 18149758185; |
| Email: |
sales-cpd@caerulumpharma.com |
| Products Intro: |
Product Name:Soticlestat
CAS:1429505-03-2
Purity:98% Package:10mg;100mg;1g;10g;100g;1kg
|
Soticlestat manufacturers
- Soticlestat
-
- $60.00 / 1mg
-
2026-01-20
- CAS:1429505-03-2
- Min. Order:
- Purity: 99.95%
- Supply Ability: 10g
|
| | Soticlestat Basic information |
| Product Name: | Soticlestat | | Synonyms: | Soticlestat;TAK-935;Methanone, [2,4'-bipyridin]-3-yl[4-hydroxy-4-(phenylmethyl)-1-piperidinyl]-;OV935;Inhibitor,CYP46A1,inhibit,cholesterol,24-hydroxylase,OV 935,Soticlestat,NMDA,antiepileptic,TAK935,CYPs,epilepsy,TAK 935,Cytochrome P450,OV-935;2,4’-Bipyridin]-3-yl(4-benzyl-4-hydroxy-1-piperidyl)methanone;Soticlestat/TAK-935/OV935;2,4'-Bipyridin]-3-yl(4-benzyl-4-hydroxypiperidin-1-yl)methanone | | CAS: | 1429505-03-2 | | MF: | C23H23N3O2 | | MW: | 373.45 | | EINECS: | | | Product Categories: | | | Mol File: | 1429505-03-2.mol |  |
| | Soticlestat Chemical Properties |
| solubility | DMSO: soluble | | form | A solid | | color | White to off-white |
| | Soticlestat Usage And Synthesis |
| Uses | Soticlestat (TAK-935; OV935) is a first-in-class, potent, selective, and orally active cholesterol 24-hydroxylase (CH24H) inhibitor. Soticlestat has the potential for epilepsy syndromes research[1][2]. | | in vivo | Soticlestat treatment lowers brain 24S-hydroxycholesterol in a dose-dependent manner and substantially reduceds premature deaths of APP/PS1-Tg mice at a dose lowering brain 24S-hydroxycholesterol by approximately 50%. Soticlestat can suppress potassium-evoked extracellular glutamate elevations in the hippocampus[1]. | Animal Model: | Amyloid precursor protein and presenilin 1 (APP/PS1-Tg) mice (7-week-old)[1] | | Dosage: | 10 mg/kg | | Administration: | Oral administration; once daily; for 1 days, 3 days and 7 days | | Result: | Lowered brain 24S-hydroxycholesterol in a dose-dependent manner and substantially reduced premature deaths of APP/PS1-Tg mice at a dose lowering brain 24S-hydroxycholesterol by approximately 50%. |
| | References | [1] Toshiya Nishi, et al. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. Sci Rep. 2020 Oct 13;10(1):17081. DOI:10.1038/s41598-020-74036-6
[2] Krista Eschbach, et al. Stiripentol for the treatment of seizures in Dravet syndrome. Expert Rev Clin Pharmacol. 2019 May;12(5):379-388. DOI:10.1080/17512433.2019.1605904 |
| | Soticlestat Preparation Products And Raw materials |
|